Experimental drug targets deadly skin cancer in rare blistering disease
NCT ID NCT03786237
First seen Feb 28, 2026 · Last updated Jun 12, 2026 · Updated 19 times
Summary
This early-phase study tested an experimental drug called rigosertib in just 2 people who have a rare, severe blistering skin disease (recessive dystrophic epidermolysis bullosa) and also developed advanced skin cancer. The goal was to see if the drug could shrink or control the cancer and to check for side effects. The study was very small and aimed to gather first information on whether rigosertib might help this specific group of patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
EB House Austria/Dept. of Dermatology University Hospital
Salzburg, State of Salzburg, 5020, Austria
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.